Prognostic Significance of Chromogranin A Expression in the Initial and Second Biopsies in Metastatic Prostate Cancer

被引：1

作者：

Huang, Zhuo ^{[1
]}

Tang, Ying ^{[2
]}

Wei, Yuyan ^{[1
]}

Qian, Jingyu ^{[1
]}

Kang, Yifan ^{[1
]}

Wang, Duohao ^{[1
]}

Xu, Miao ^{[1
]}

Nie, Ling ^{[1
]}

Chen, Xueqin ^{[1
]}

Chen, Ni ^{[1
]}

Zhou, Qiao ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu 610041, Peoples R China

[2] Chengdu Med Coll, Affiliated Hosp 1, Dept Pathol, Chengdu 610500, Peoples R China

来源：

JOURNAL OF CLINICAL MEDICINE | 2023年 / 12卷 / 10期

基金：

中国国家自然科学基金;

关键词：

prostate cancer; CgA expression; overall survival; prognosis; NEUROENDOCRINE DIFFERENTIATION; SERUM-LEVELS; MARKER; PREDICTION; PATHWAY;

D O I：

10.3390/jcm12103362

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Neuroendocrine differentiation (NED) characterized by the expression of neuroendocrine markers, such as chromogranin A (CgA), is frequently observed in advanced prostate cancer (PCa), the prognostic significance of which is still controversial. Here we specifically addressed the issue of the potential prognostic value of CgA expression in advanced-stage PCa patients with distant metastases and its change over time from metastatic hormone-sensitive (mHSPC) to metastatic castration-resistant prostate cancer (mCRPC). CgA expression was assessed immunohistochemically in initial biopsies of mHSPC, as well as in second biopsies of mCRPC in sixty-eight patients, and its correlation with prognosis (together with conventional clinicopathologic parameters) was analyzed using the Kaplan-Meier method and Cox proportional hazard model. We found that CgA expression was an independent adverse prognostic factor for both mHSPC (CgA positivity = 1%, HR = 2.16, 95% CI: 1.04-4.26, p = 0.031) and mCRPC (CgA = 10%, HR = 20.19, 95% CI: 3.04-329.9, p = 0.008). CgA positivity generally increased from mHSPC to mCRPC and was a negative prognosticator. The assessment of CgA expression may help with the clinical evaluation of advanced-stage patients with distant metastases.

引用

页数：12

共 45 条

[1] Genomic correlates of clinical outcome in advanced prostate cancer [J].

Abida, Wassim ;

Cyrta, Joanna ;

Heller, Glenn ;

Prandi, Davide ;

Armenia, Joshua ;

Coleman, Ilsa ;

Cieslik, Marcin ;

Benelli, Matteo ;

Robinson, Dan ;

Van Allen, Eliezer M. ;

Sboner, Andrea ;

Fedrizzi, Tarcisio ;

Mosquera, Juan Miguel ;

Robinson, Brian D. ;

De Sarkar, Navonil ;

Kunju, Lakshmi P. ;

Tomlins, Scott ;

Wu, Yi Mi ;

Rodrigues, Daniel Nava ;

Loda, Massimo ;

Gopalan, Anuradha ;

Reuter, Victor E. ;

Pritchard, Colin C. ;

Mateo, Joaquin ;

Bianchini, Diletta ;

Miranda, Susana ;

Carreira, Suzanne ;

Rescigno, Pasquale ;

Filipenko, Julie ;

Vinson, Jacob ;

Montgomery, Robert B. ;

Beltran, Himisha ;

Heath, Elisabeth I. ;

Scher, Howard I. ;

Kantoff, Philip W. ;

Taplin, Mary-Ellen ;

Schultz, Nikolaus ;

deBono, Johann S. ;

Demichelis, Francesca ;

Nelson, Peter S. ;

Rubin, Mark A. ;

Chinnaiyan, Arul M. ;

Sawyers, Charles L. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (23) :11428-11436

[2] Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study [J].

Aggarwal, Rahul ;

Huang, Jiaoti ;

Alumkal, Joshi J. ;

Zhang, Li ;

Feng, Felix Y. ;

Thomas, George V. ;

Weinstein, Alana S. ;

Friedl, Verena ;

Zhang, Can ;

Witte, Owen N. ;

Lloyd, Paul ;

Gleave, Martin ;

Evans, Christopher P. ;

Youngren, Jack ;

Beer, Tomasz M. ;

Rettig, Matthew ;

Wong, Christopher K. ;

True, Lawrence ;

Foye, Adam ;

Playdle, Denise ;

Ryan, Charles J. ;

Lara, Primo ;

Chi, Kim N. ;

Uzunangelov, Vlado ;

Sokolov, Artem ;

Newton, Yulia ;

Beltran, Himisha ;

Demichelis, Francesca ;

Rubin, Mark A. ;

Stuart, Joshua M. ;

Small, Eric J. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (24) :2492-+

[3] The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia [J].

Bech, P. R. ;

Martin, N. M. ;

Ramachandran, R. ;

Bloom, S. R. .

ANNALS OF CLINICAL BIOCHEMISTRY, 2014, 51 (01) :8-21

[4] Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer [J].

Beltran, Himisha ;

Prandi, Davide ;

Mosquera, Juan Miguel ;

Benelli, Matteo ;

Puca, Loredana ;

Cyrta, Joanna ;

Marotz, Clarisse ;

Giannopoulou, Eugenia ;

Chakravarthi, Balabhadrapatruni V. S. K. ;

Varambally, Sooryanarayana ;

Tomlins, Scott A. ;

Nanus, David M. ;

Tagawa, Scott T. ;

Van Allen, Eliezer M. ;

Elemento, Olivier ;

Sboner, Andrea ;

Garraway, Levi A. ;

Rubin, Mark A. ;

Demichelis, Francesca .

NATURE MEDICINE, 2016, 22 (03) :298-305

[5] The Prognostic Role of Immunohistochemical Chromogranin A Expression in Prostate Cancer Patients Is Significantly Modified by Androgen-Deprivation Therapy [J].

Berruti, Alfredo ;

Bollito, Enrico ;

Cracco, Cecilia M. ;

Volante, Marco ;

Ciccone, Giovannino ;

Porpiglia, Francesco ;

Papotti, Mauro ;

Scarpa, Roberto Mario ;

Dogliotti, Luigi .

PROSTATE, 2010, 70 (07) :718-726

[6] Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling [J].

Bluemn, Eric G. ;

Coleman, Ilsa M. ;

Lucas, Jared M. ;

Coleman, Roger T. ;

Hernandez-Lopez, Susana ;

Tharakan, Robin ;

Bianchi-Frias, Daniella ;

Dumpit, Ruth F. ;

Kaipainen, Arja ;

Corella, Alexandra N. ;

Yang, Yu Chi ;

Nyquist, Michael D. ;

Mostaghel, Elahe ;

Hsieh, Andrew C. ;

Zhang, Xiaotun ;

Corey, Eva ;

Brown, Lisha G. ;

Nguyen, Holly M. ;

Pienta, Kenneth ;

Ittmann, Michael ;

Schweizer, Michael ;

True, Lawrence D. ;

Wise, David ;

Rennie, Paul S. ;

Vessella, Robert L. ;

Morrissey, Colm ;

Nelson, Peter S. .

CANCER CELL, 2017, 32 (04) :474-+

[7] Parallel Determination of NeuroD1, Chromogranin-A, KI67 and Androgen Receptor Expression in Surgically Treated Prostate Cancers [J].

Cindolo, L. ;

Cantile, M. ;

Franco, R. ;

Chiodini, P. ;

Schiavo, G. ;

Forte, I. ;

Zlobec, I. ;

Salzano, L. ;

Botti, G. ;

Gidaro, S. ;

Terracciano, L. ;

Cillo, C. .

INTERNATIONAL BRAZ J UROL, 2011, 37 (01) :57-66

[8] Clinical features of neuroendocrine prostate cancer [J].

Conteduca, Vincenza ;

Oromendia, Clara ;

Eng, Kenneth W. ;

Bareja, Rohan ;

Sigouros, Michael ;

Molina, Ana ;

Faltas, Bishoy M. ;

Sboner, Andrea ;

Mosquera, Juan Miguel ;

Elemento, Olivier ;

Nanus, David M. ;

Tagawa, Scott T. ;

Ballman, Karla V. ;

Beltran, Himisha .

EUROPEAN JOURNAL OF CANCER, 2019, 121 :7-18

[9] Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide [J].

Conteduca, Vincenza ;

Burgio, Salvatore Luca ;

Menna, Cecilia ;

Carretta, Elisa ;

Rossi, Lorena ;

Bianchi, Emanuela ;

Masini, Carla ;

Amadori, Dino ;

De Giorgi, Ugo .

PROSTATE, 2014, 74 (16) :1691-1696

[10] EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer [J].

Cornford, Philip ;

Bellmunt, Joaquim ;

Bolla, Michel ;

Briers, Erik ;

De Santis, Maria ;

Gross, Tobias ;

Henry, Ann M. ;

Joniau, Steven ;

Lam, Thomas B. ;

Mason, Malcolm D. ;

van der Poel, Henk G. ;

van der Kwast, Theo H. ;

Rouviere, Olivier ;

Wiegel, Thomas ;

Mottet, Nicolas .

EUROPEAN UROLOGY, 2017, 71 (04) :630-642

← 1 2 3 4 5 →